Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1642 1644 1671 1681
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18034621 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL EXPRESSING CXCL12 RECEPTOR | Non-Final OA | RIKEN |
| 18263008 | ENHANCING METABOLIC FITNESS OF T CELLS TO TREAT CANCER | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18261983 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | Non-Final OA | Baylor College of Medicine |
| 18368647 | METHODS OF PERSONALIZED PRECONDITIONING FOR CELL THERAPY | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18272539 | ANTI-HUMAN CD22 MONOCLONAL ANTIBODIES AND USE THEREOF | Non-Final OA | Simcere Zaiming Pharmaceutical Co., Ltd. |
| 18460246 | TREATMENT OF HERPES SIMPLEX VIRUS INFECTION | Non-Final OA | United BioPharma, Inc. |
| 18275481 | METHODS FOR PREVENTING ORAL SENSITIZATION | Non-Final OA | MY-OR DIAGNOSTICS LTD. |
| 18360742 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | Non-Final OA | CHIGENOVO CO., LTD. |
| 18273661 | CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND NK CELLS EXPRESSING CAR CONSTRUCTS | Non-Final OA | CYTOCARES (SHANGHAI) INC. |
| 18265591 | Anti-Human MSLN Antibody And Application Thereof | Non-Final OA | NANJING ZAIMING PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy